Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer

TLDR: In this article, a thorough literature review was performed, analyzing all recent studies regarding surgical morbidity and mortality regarding non-small cell lung cancer (NSCLC) patients with ipsilateral positive mediastinal nodes.

Abstract: Multimodality therapy for locally advanced non-small cell lung cancer (NSCLC) is a complex and controversial issue, especially regarding optimal treatment regimens for patients with ipsilateral positive mediastinal nodes (N2 disease) Many trials investigating neoadjuvant immunotherapy and targeted therapy in this subpopulation have shown promising results, although concerns have risen regarding surgical feasibility A thorough literature review was performed, analyzing all recent studies regarding surgical morbidity and mortality Despite the fact that two major trials investigating this subject were terminated early, the overall consensus is that surgical management seems feasible However, dissection of hilar vessels may be challenging due to hilar fibrosis Further research is necessary to identify the role of surgery in these multimodality treatment regimens, and to define matters such as the optimal treatment regimen, the dosage of the different agents used, the interval between induction therapy and surgery, and the role of adjuvant therapy